Blueprint Medicineswill host a live conference call and webcast at8:30 a.m. View jobs Working at Blueprint Medicines: 7 Reviews Review this company Job Title All Location United States 7 reviews Ratings by category 3.7 Work-Life Balance 4.3 Pay & Benefits 2.8 Job Security & Advancement 2.8 Management 3.0 Culture Sort by Helpfulness Rating Date Language We aim to develop treatments that can penetrate into the brain, so they may prevent or treat tumor formation. CAMBRIDGE, Mass., Nov. 1, 2022 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC) today announced its 2027 Blueprint to achieve precision medicine at scale, a five-year business strategy to. enva un correo electrnico a Blueprint Medicines Location Avg. Lamentamos These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts. Please enable Cookies and reload the page. envie um e-mail para CDK2 and Cyclin E (CCNE1) are central to regulating the cell cycle, which is involved in the process of cell growth and division. Its important to have different perspectives within your team and in your workplace. Read the press release, Published results from the TouchStone study of patient and healthcare provider perceptions of SM disease burden, which highlighted that SM is associated with severe and burdensome symptoms including anaphylactic events, frequent emergency department visits, use of multiple symptom-directed medications, reduced ability to work, impaired physical functioning and poor quality of life. Individual salaries will, of course, vary depending on the job, department, location, as well as the individual skills and education of each employee. I am responsible for developing the regulatory strategy across our portfolio of genetically targeted kinase inhibitors. Caso continue recebendo esta mensagem, Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail The average . Her love for the sciences never wavered, though. By signing up you agree to receive content from us. message, contactez-nous l'adresse What advice do you have for other women who are striving to achieve leadership roles? We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance. "In bringing pralsetinib to patients, we will leverage our global reach and expertise in oncology, as well as our capabilities in diagnostics and the use of real-world data toward our aim of providing personalised treatments for patients.". excuses voor het ongemak. Present initial data from the Phase 1/2 CONCERTO study of BLU-451 in patients with EGFR-mutant NSCLC in the first half of 2023. The Senior Accountant will work across functions and teams at Blueprint Medicines as a trusted partner to facilitate efficient communication to support the Company's financial processes. Learn more about who we are and explore our career opportunities below to join us on this journey. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. an. The forecasts range from a low of 42.42 to a high of $119.70. If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro. questo messaggio, invia un'email all'indirizzo This rating has decreased by -4% over the last 12 months. Wir entschuldigen uns fr die Umstnde. Please help us protect Glassdoor by verifying that you're a At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined cancers and rare diseases. Disculpa Cautionary Note Regarding Forward-Looking Statements. Lauren Barnes Work Experience and Education. We aim to develop a new treatment option that targets this underlying cause of tumor growth. Blueprint Medicines Corp pays an average salary of $113,989 and salaries range from a low of $99,092 to a high of $131,862. . In honor of International FOP Awareness Day, our Chief Scientific Officer Marion Dorsch shares a letter to the patient community highlighting our commitment to advance care and raise awareness for those affected by this rare genetic disease. Yes No ZIPPIA SCORE Blueprint Medicines Salaries 9.7 Score The national average salary for a Blueprint Medicines employee in the United States is $84,447 per year or $41 per hour. enviando un correo electrnico a It creates a huge sense of purpose for me and its what gets me out of bed feeling excited to do what I do to support our teams and business, she says. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery. Submit a supplemental New Drug Application to the FDA for AYVAKIT for non-advanced SM in the fourth quarter of 2022. As a leader, I think its important to be vulnerable, which helps build trust and psychological safety. CDK2 is believed to play an important role in tumor growth for patients with hormone receptor-positive, HER2-negative breast cancer. What skills and traits have helped you succeed? Transparency and communication are key to keeping your people engaged and I also think its very important to provide the tools people need to get their work done efficiently, removing redundancies and barriers. All rights reserved. What challenges have you faced as a woman in a leadership role, and how have you overcome them? Introduce a new research program targeting wild-type KIT, which aims to build on the company's KIT target leadership to advance a best-in-class oral precision therapy for common mast cell diseases adjacent to systemic mastocytosis, including chronic urticaria. Announced positive top-line results from the registration-enabling Part 2 of the PIONEER trial of AYVAKIT in patients with non-advanced SM, demonstrating clinically meaningful and highly significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden. Compared to BLU-701, BLU-525 has a distinct chemical structure with improved kinome selectivity and differentiated metabolism, and equivalent EGFR mutation coverage, wild-type EGFR selectivity, and central nervous system penetration. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery. Early Career Programs | Blueprint Medicines College Internship & Co-op Program We recruit students from colleges and universities across the country to participate in three- or six-month-long assignments spanning all departments at Blueprint. At Blueprint Medicines, we are motivated by one goal: to dramatically improve the lives of people with cancer and rare diseases. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plans in continuing to establish and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines'ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines' ability to realize the anticipated benefits of its executive leadership transition plan; and the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements. Si continas viendo este mensaje, Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail Read the press release, As previously recorded and reported by Roche, GAVRETO global product sales were. Blueprint Medicines is a precision therapy company striving to improve human health. Working at Blueprint Medicines: Employee Reviews about Pay & Benefits | Indeed.com Start of main content Blueprint Medicines 3.7 7 reviews Write a review Snapshot Why Join Us 14 Jobs 7 Reviews 165 Salaries 1 Q&A Interviews 1 Photos Want to work here? Tap into our managers expertise to lead your team towards success by providing sound decision-making skills, effective communication techniques and clear expectations. Bitte helfen Sie uns, Glassdoor zu schtzen, indem Sie besttigen, dass Sie "This morning at our Investor Day, we will highlight our 2027 Blueprint strategy to double our impact in five years across multiple metrics of portfolio strength. Also, empowering all employees to feel safe and to have the space to be open and share their collective experiences is how we build a better workplace and support belonging. 81% of employees would recommend working at Blueprint Medicines to a friend and 91% have a positive outlook for the business. enviando un correo electrnico a message, please email Blueprint Medicines is a global precision therapy company that aims to invent life-changing therapies for people with cancer and rare diseases. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. By suppressing primary and secondary mutants, pralsetinib has the potential to overcome and prevent the emergence of clinical resistance. Why does the work youre doing at Blueprint Medicines excite and inspire you? Ci This current average has increased by 19.46% from the previous average price target of $57.82. Onze According to ZoomInfo records, Lauren Barnes's professional experience began in 1996. Below is a summary of how these 15 analysts rated Blueprint Medicines over the past 3 months. "With Roche's global reach and unparalleled expertise in personalized healthcare, this collaboration will accelerate our ability to bring pralsetinib to patients with significant medical needs around the world and expand development of pralsetinib across multiple treatment settings where there is potential to benefit even broader patient populations," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. Within this circle, I learned more about myself in terms of what drives me, how I can show up better, and ultimately how to ground myself when I am feeling anxious or stressed. There are several forms of SM including indolent SM and advanced SM. Growing up, Tanya Green wanted to be a marine biologist because she loved whales and dolphins and wanted to spend her time out on the ocean to study them, but it didnt work out as shed envisioned. View jobs Blueprint Medicines Pay & Benefits reviews Review this company Job Title All Location Se continui a visualizzare Jul 05, 2023 Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 05, 2023 Blueprint Medicines Announces . Ci In subsets of patients with ovarian cancer and other tumor types, CCNE1 hyperactivates CDK2, resulting in tumor formation. A replay of the webcast will be archived on Blueprint Medicines' website for 90 days following the event. The Muse offers expert advice, job opportunities, a peek behind the scenes at companies hiring now, and career coaching services. los inconvenientes que esto te pueda causar. Lamentamos Aydanos a proteger Glassdoor y demustranos que eres una persona real. We combine a deep understanding of the genetic blueprint of cancer and rare diseases with expertise in kinase biology to craft precision therapies specifically designed to target the underlying molecular basis of disease. The company plans to submit an investigational new drug application to the U.S. Food and Drug Administration (FDA) for BLU-525 in the first quarter of 2023. Explore working for Blueprint Medicines and see what it's like to work in the area. Clinical trials are an important part of helping to bring safe and effective medicines to patients. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call. To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 9477613. We aim to address a need for precision therapies that provide durable clinical benefit by selectively targeting RET alterations and resistance mutations. 11, 2023 Find Reviews Clear All Full-time, Part-time English Filter Found 37 of over 47 reviews Sort Popular Popular Most Recent Highest Rating Lowest Rating 3.9 81 % Recommend to a Friend 93 % Approve of CEO Kate Haviland Cision Distribution 888-776-0942 Visit YourBlueprint.com for more information, Visit our Corporate Funding portal to learn more about our support of independently developed patient education programs and resources, Learn more about participating in clinical trials, Do Not Sell Or Share My Personal Information, Limit The Use Of My Sensitive Information. Si continas recibiendo este mensaje, infrmanos del problema In patients with SM, mast cells produce high levels of these mediators, causing debilitating symptoms including pain, nausea, rash, fatigue and anaphylaxis. enviando un correo electrnico a Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plan in establishing a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug candidates or licensed product candidate; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for its current and future drug candidates; and the success of Blueprint Medicines' current and future collaborations or licensing arrangements. The collaboration combines Blueprint Medicines' pralsetinib and precision therapy expertise with Roche's global reach, integrated personalized healthcare capabilities and portfolio of cancer therapies. envie um e-mail para Overview 0 Jobs Compensation 1 Experts Average Compensation: $ 135,065 Average Compensation $ 135,065 $80K $100K $120K $140K $160K National Average How Much Do Blueprint Medicines Employees. Currently, Lauren Barnes works as a Senior Vice President, Market Access at Blueprint Medicines. para informarnos de que tienes problemas. Overview 48 Reviews 15 Jobs 131 Salaries 25 Interviews 44 Benefits 35 Photos 23 Diversity + Add a Review Blueprint Medicines Boston Reviews Updated May 31, 2023 Filter by Topic Work Life Balance Coworkers Culture Career Development Workplace Benefits Compensation Management Senior Leadership Search Reviews Search Reviews Filter by Job Title We are working to advancea deep pipeline of precision therapies, designed to allow patients to live longer, better lives. per informarci del problema. Nous sommes dsols pour la gne occasionne. The companies also plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor as part of this collaboration. Managers are responsible for leading teams toward meeting goals by setting objectives, implementing plans, delegating tasks and monitoring progress. an. Other job titles include Team Leader or Supervisor. , . ", "In addition, today we are reaffirming total revenue guidance for full-year 2022, while we lower product revenue guidance based on performance in the third quarter and our near-term expectations for growth. The average Blueprint Medicines salary ranges from approximately $48,000 per year for Quality Control Supervisor to $293,000 per year for Director of Business Development. Earlier in my career, I had a hard time balancing my work with my personal family obligations. With this approach, we aim to develop breakthrough medicines that allow patients to live longer, healthier lives. Applying an approach that is both precise and agile,. At Blueprint Medicines, we work together toward one common goal: to develop breakthrough precision medicines that allow patients to live longer, healthier lives. Gastrointestinal stromal tumor, or GIST, accounts for the most common sarcoma of the gastrointestinal tract, or GI tract. In addition, Blueprint Medicines has submitted a marketing authorization application to the European Medicines Agency for pralsetinib for the treatment of RET fusion-positive NSCLC. Through this role, I met regulatory affairs professionals and really liked their role within the company. My previous boss and mentor reached out to see if I was interested in interviewing for a regulatory position working on the lead program. At the American Association for Cancer Research (AACR) Annual Meeting 2022, we presented new clinical and preclinical data for multiple programs across genomically defined cancers, including lung, ovarian and breast cancers. About Blueprint Medicines. Our world-leading expertise in protein kinases, which are proven drivers of disease, powers the relentless development of transformational medicines. I think this is critical to our culture and, at the end of the day, this type of collaboration drives productivity. message, please email In addition, Blueprint Medicines today reported financial results and provided a business update for the third quarter ended September 30, 2022. Find out what works well at Blueprint Medicines from the people who know best. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease. The live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com/. para informarnos de que tienes problemas. Industry Biotechnology Location Cambridge, MA + 1 more Size 501 - 1,000 employees Perks and Benefits Health & Wellness and more Working at Blueprint Medicines This created a huge amount of guilt not being more available for my husband and young children. We are sorry for the inconvenience. It was as if I was constantly trying to keep up, so I would bring my work home. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for interactions with the FDA and other regulatory authorities; to submit a supplemental New Drug Application to the FDA for AYVAKIT in non-advanced SM, with a subsequent submission of a type II variation marketing authorization application to the European Medicines Agency; plans and timing for presenting detailed data from the PIONEER trial of AYVAKIT in patients with non-advanced SM, and, expectations regarding the potential benefits of AYVAKIT in treating patients with non-advanced SM; statements regarding plans and expectations for Blueprint Medicines' current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; andBlueprint Medicines'financial performance, strategy, goals and anticipated milestones, business plans and focus. Here, Green shares her thoughts on equity,diversity, and inclusion at Blueprint Medicines, becoming an effective leader, and finding work-life balance. There have been studies showing that women are less self-assured than men, and that for us to succeed we need to have confidence as a core competency. Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecul, United States, Massachusetts. . Glassdoor gives you an inside look at what it's like to work at Blueprint Medicines, including salaries, reviews, office photos, and more. Based on emerging clinical and preclinical data, Blueprint Medicines plans to prioritize development of BLU-525, a back-up EGFR inhibitor candidate, and deprioritize further development of BLU-701. Compare pay for popular roles and read about the team's work-life balance. En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. Targeting cancers vulnerable to CDK2 inhibition has the potential to deliver meaningful benefits for a broad range of patients. Wenn Marketing applications for pralsetinib are submitted or planned for RET fusion-positive NSCLC, RET mutation-positive MTC and RET fusion-positive thyroid cancer in the U.S., Europe and other geographies. Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. -- On track to submit supplemental new drug application for AYVAKIT (avapritinib) in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023 --, -- Reports updated data from the SYMPHONY trial of BLU-945 demonstrating clinical activity and a differentiated safety profile, supporting combination development in first-line EGFR-mutant non-small cell lung cancer --, -- Expects to achieve the high-end of total revenue guidance of $180 million to $200 million for full-year 2022 --, -- Blueprint Medicines to webcast Investor Day 2022 event today at 8:30 a.m. Ci I lead Blueprint Medicines global regulatory sciences department, which includes global regulatory and clinical strategy, chemistry manufacturing and controls (CMC), regulatory operations, advertising and promotion, intelligence, and compliance. Ideas come from everywhere, from the C-suite to new hires, and each day we commit to approach one another with respect and trust. Blueprint Medicines believes this approach will enable durable clinical responses across a diverse range of RET alterations, with a favorable safety profile. Company Blueprint Medicines Regina Nizzoli Current Workplace Regina Nizzoli has been working as a Associate Director, Field Marketing, Northwest At Blueprint Medicines at Blueprint Medicines for 3 years. Lamentamos pelo inconveniente. How would you describe your leadership style? The closing of a minority portion of the equity investment is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. There were a few actions I took to help me overcome these challenges. Dont let your inner critic get the best of you. Si continas viendo este mensaje, In the U.S., Blueprint Medicines and Genentech will work together to co-commercialize pralsetinib, with the companies equally sharing responsibilities, profits and losses. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, torapidly and reproducibly translate science into a broad pipeline of precision therapies. I decided to learn more about regulatory and went back and got a masters degree in regulatory affairs and health policy from Massachusetts College of Pharmacy and Health Sciences. Employment opportunities Learn more Contract opportunities Explore Talent Community Join As a biotechnology organization, it is our responsibility to do everything we can to support the health and safety of our Blue Crew, our communities and the patients we serve. In addition to multiple research programs, we are currently advancing investigational medicines in clinical development for a broad range of genomically defined cancers and rare diseases. Tell us about Blueprint Medicines equity, diversity, and inclusion initiatives and your involvement in them. Lastly, I found ways to focus on my own well-being, such as spending more quality time with my family (by enforcing sit-down family dinners a few nights a week), mediating, and getting physical (gym classes at 5AM and womens soccer one night a week). A common site of tumor progression is the central nervous system. Aiutaci a proteggere Glassdoor dimostrando che sei una persona reale. . 8d ago Patients diagnosed at an early stage may undergo surgery. What are you responsible for in your role, and what are some unique challenges to your job? 86% of retail CFD accounts lose money, 3 Biotech Stocks Using AI to Change Healthcare Forever, Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Regeneron (REGN) and Blueprint Medicines (BPMC), Roche pulls thyroid cancer indication for Gavreto, Analyst Expectations for Blueprint Medicines's Future, 3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon, Registration on or use of this site constitutes acceptance of our. What is the best career advice youve ever received. Lamentamos pelo inconveniente. Skip to Main Content. The FDA has accepted the MTC NDA for its Real-Time Oncology Review (RTOR) pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. ET to discuss the collaboration. Craig Hill Current Workplace Craig Hill has been working as a Senior Director, Facilities Management at Blueprint Medicines for 8 years. For more information, contact our medical information department: [email protected].